Jayson Bedford
Stock Analyst at Raymond James
(3.98)
# 486
Out of 4,842 analysts
311
Total ratings
56.36%
Success rate
7.63%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $328 → $360 | $323.24 | +11.37% | 27 | May 27, 2025 | |
| ICUI ICU Medical | Maintains: Strong Buy | $197 → $187 | $134.05 | +39.50% | 20 | May 9, 2025 | |
| MASI Masimo | Maintains: Outperform | $204 → $185 | $154.84 | +19.48% | 7 | May 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $119 → $104 | $92.80 | +12.08% | 8 | May 6, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $116 → $108 | $94.56 | +14.21% | 27 | Apr 25, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $132 → $142 | $132.90 | +6.85% | 28 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $162 → $164 | $153.27 | +7.00% | 23 | Apr 16, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $119 → $122 | $104.46 | +16.79% | 24 | Feb 6, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $560 → $688 | $557.23 | +23.47% | 8 | Jan 24, 2025 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $84.66 | +16.94% | 30 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $173.76 | +55.39% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.84 | +19.93% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $9.98 | +0.20% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $122.18 | +121.80% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.55 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.51 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $77.71 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.70 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $82.28 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.53 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $63.06 | +36.39% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.54 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.61 | - | 3 | Jan 2, 2018 |
Insulet
May 27, 2025
Maintains: Outperform
Price Target: $328 → $360
Current: $323.24
Upside: +11.37%
ICU Medical
May 9, 2025
Maintains: Strong Buy
Price Target: $197 → $187
Current: $134.05
Upside: +39.50%
Masimo
May 7, 2025
Maintains: Outperform
Price Target: $204 → $185
Current: $154.84
Upside: +19.48%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $119 → $104
Current: $92.80
Upside: +12.08%
Merit Medical Systems
Apr 25, 2025
Maintains: Outperform
Price Target: $116 → $108
Current: $94.56
Upside: +14.21%
Abbott Laboratories
Apr 17, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $132.90
Upside: +6.85%
Johnson & Johnson
Apr 16, 2025
Maintains: Outperform
Price Target: $162 → $164
Current: $153.27
Upside: +7.00%
Boston Scientific
Feb 6, 2025
Maintains: Strong Buy
Price Target: $119 → $122
Current: $104.46
Upside: +16.79%
Intuitive Surgical
Jan 24, 2025
Maintains: Outperform
Price Target: $560 → $688
Current: $557.23
Upside: +23.47%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $84.66
Upside: +16.94%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $173.76
Upside: +55.39%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $10.84
Upside: +19.93%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $9.98
Upside: +0.20%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $122.18
Upside: +121.80%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.55
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $21.51
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $77.71
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $30.70
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $82.28
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.53
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $63.06
Upside: +36.39%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.54
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $12.61
Upside: -